

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A06/2017 OS

DESPATCHED ON 23 MAY 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A-; B7, B-; Cw7, Cw-; DR13, DR15; DQ6, DQ-

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	15	14	15	15	32	32	31	32	27	28	29	26				
Positive	1	5	13	2	0	0	27	0	2	28	25	1				
Negative	14	9	2	13	32	32	4	32	25	0	4	25				
NT/Equivocal	0	1	0	0	6	6	7	6	12	11	10	13				
% Positive	6.7%	35.7%	86.7%	13.3%	0.0%	0.0%	87.1%	0.0%	7.4%	100.0%	86.2%	3.8%				
% Negative	93.3%	64.3%	13.3%	86.7%	100.0%	100.0%	12.9%	100.0%	92.6%	0.0%	13.8%	96.2%				
Consensus	Negative	Not Assessed	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative				
HLA Antibody Specificity (Defined By CDC)	A32 B44 DR7	DR5 DR6 DQ6	A3	DQ3	A32 B44 DR7	DR5 DR6 DQ6	A3	DQ3	A32 B44 DR7	DR5 DR6 DQ6	A3	DQ3				
				Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
101	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
112	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Cells treated with Percoll 40%
114	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Samples were not received
116	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
119	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	Positive	Negative	
120	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
128	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
133	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
139	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
143	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
145	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
147	YES	YES	YES	Negative	Positive	Positive	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Equivocal	Unable to test Class II/B cells
154	YES	YES	YES	Negative	Positive	Positive	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	NT. Due to holidays in France (day of the ascent) and kidney pre transplant cross match in emergencies we could not test cytotoxic crossmatching scheme 2A with 2A05 and 2A06 samples before the 26th may. Samples were kept at 4°C but it is known to decrease HLA expression and sensitivity of the CDC. It is an unauthorized practice in our Lab. Impossible to perform CDC test, because we received a recall notice of Class II Dynabeads from ThermoFisher. We still did not have a replacement reagent available.
157	YES	YES	YES	Negative	Positive	Positive	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	
159	YES	YES	YES	Negative	Positive	Positive	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
162	YES	YES	YES	Negative	Positive	Positive	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
163	YES	YES	YES	Negative	Positive	Positive	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
169	YES	YES	YES	Negative	Positive	Positive	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
181	YES	YES	YES	Negative	Positive	Positive	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
186	YES	YES	YES	Negative	Positive	Positive	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
189	YES	YES	YES	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	
190	YES	YES	YES	Negative	Positive	Positive	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	B cells NT due to use of Dynabeads HLA class II catalog number 21003 Lot number 00461955.
193	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
194	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
195	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	No B cells found in the samples
197	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
204	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
206	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
209	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Dynabeads issue
216	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
223	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Samples were not tested due to national holiday
227	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Technical failure
229	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
232	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
235	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
238	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
239	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
245	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
252	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
259	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
260	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
262	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
268	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Low viability on B cells because we have a big problem with new lot of class II immunomagnetics beads (one lambda)
284	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
292	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
293	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Samples were received on 26th May instead of 25th May, morphology of the cells and viability of the cells very poor, therefore samples were NT.
294	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
297	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
321	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Insufficient number of B cells, technical failure with T cells
351	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Cell viability too low to perform tests (60%)

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A06/2017 OS

DESPATCHED ON 23 MAY 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					1	1	1	1	1	6	1	1	90		
112	1	1	8	1											
114					1	1	1	1	1	8	2	1			
116															
119	1	1	8	1									95		
120					1	1	8	1	2	8	8	1		100	100
128	1	1	1	1									98		
133					2	2	8	2	2	8	8	2	95	95	80
139	1	1	8	1	1	1	8	1	1	8	8	1	85	85	85
143					1	1	4	1						89.2	
145							8			8	8			100	80
147	1	4	8	4	1	1	8	1	2	8	8	6	100	100	100
154															
157															
159					1	1	8	1	1	8	6	1		99	99
162							8			8	8			100	100
163					1	1	8	1	1	8	6-8	1		90	90
169					1	1	6	1		8	8			97	97
181					1	1	8	1	1	8	8	1	100	100	100
186					0	0	4	0	0	8	4	0		99	99
189	4	6	1	4									95		
190					1%	1%	1%	1%						99	60
193	1	2	8	1	1	1	8	1	1	8	8	1	97	98	95
194															
195					1	1	8	1						>95	
197							Weak						100	95	95
204					1	1	8	1	2	8	8	2		100	95
206					0	0	8	0	0	8	8	0		95	80
209	1	4	4	1									90		
216	1	1	4	1									85		
223															
227							8				8			98	98
229															
232	0%	0%	75%	0%									80		
235	1	1	8	1									85		
238	1	4	8	1	1	1	8	1	1	8	4	1	95	95	80
239	1	1	6	1	1	1	6	1	1	8	1	1	90	90	90
245	1	2	6	1	1	1	6	1	1	8	6	1	100	100	100
252	2	2	6	2					2	6	6	2	85	70	
259															
260	NT	NT	NT	NT	-	-	-	-	-	++++	-	-		90	80
262													100	100	100
268					1	1	8	1	1	4	2	1		98	80
284					1	1	8	1	1	8	8	1		97	30
292					1	1	6	1	4	8	6	1		85	60
293													12	10	5
294					0	0	8	0	0	8	8	0		95	90
297					1	1	8	1	1	6	8	1	80	80	80
321					1	1		1						95	20
351															

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A06/2017 OS

DESPATCHED ON 23 MAY 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A-; B7, B-; Cw7, Cw-; DR13, DR15; DQ6, DQ-

				Summary of Results												
				PBL				T-Cells				B-Cells				
				13	12	13	13	31	31	30	31	25	26	26	25	
				1	5	11	2	0	0	24	0	2	26	23	1	
				12	7	2	11	31	31	6	31	23	0	3	24	
				0	1	0	0	3	3	4	3	11	10	10	11	
				7.7%	41.7%	84.6%	15.4%	0.0%	0.0%	80.0%	0.0%	8.0%	100.0%	88.5%	4.0%	
				92.3%	58.3%	15.4%	84.6%	100.0%	100.0%	20.0%	100.0%	92.0%	0.0%	11.5%	96.0%	
Consensus				Negative	Not Assessed	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
HLA Antibody Specificity (Defined By CDC)				A32 B44 DR7	DR5 DR6 DQ6	A3	DQ3	A32 B44 DR7	DR5 DR6 DQ6	A3	DQ3	A32 B44 DR7	DR5 DR6 DQ6	A3	DQ3	
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
101	YES	YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
112	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Cells treated with Percoll 40%
114		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Samples were not received
116		YES	YES													
119	YES			Negative	Negative	Negative	Negative									
120		YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
128																
133		YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
139	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
143		YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
145																
147	YES	YES	YES	Negative	Positive	Positive	Positive	Negative	Negative	Positive	Negative	NT	NT	NT	NT	Unable to test Class II/B cells
154																
157			YES									NT	NT	NT	NT	Impossible to perform CDC test, because we received a recall notice of Class II Dynabeads from ThermoFisher. We still did not have a replacement reagent available.
159	YES	YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
162	YES	YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
163	YES	YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
169	YES	YES	YES					Negative	Negative	Positive	Negative	Equivocal	Positive	Positive	Equivocal	
181	YES	YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
186	YES	YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
189	YES			Positive	Positive	Negative	Positive									
190	YES	YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	B cells NT due to use of Dynabeads HLA class II catalog number 21003 Lot number 00461955.
193	YES	YES	YES	Negative	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
194		YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
195		YES	YES					Negative	Negative	Positive	Negative	NT	NT	NT	NT	No B cells found in the sampels
197		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
204		YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
206		YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
209	YES		YES	Negative	Positive	Positive	Negative					NT	NT	NT	NT	Dynabeads issue
216	YES		YES	Negative	Negative	Positive	Negative									
223																Samples were not tested due to national holiday
227		YES	YES					Negative	Negative	Positive	Negative	NT	NT	Positive	NT	Technical failure
229	YES															
232																
235	YES			Negative	Negative	Positive	Negative									
238	YES	YES	YES	Negative	Positive	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
239																
245	YES	YES	YES	Negative	Positive	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
252	YES		YES	Negative	Negative	Positive	Negative					Negative	Positive	Positive	Negative	
259																
260		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
262	YES	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	Equivocal	Positive	S3 B CELLS : neg control failed
268		YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
284		YES	YES													Low viability on B cells because we have a big problem with new lot of class II immunomagnetics beads (one lambda)
292	YES	YES	YES					Negative	Negative	Positive	Negative	Positive	Positive	Positive	Negative	
293		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Samples were received on 28th May instead of 25th May, morphology of the cells and viability of the cells very poor, therefore samples were NT.
294		YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
297		YES	YES					Negative	Negative	Positive	Negative	Negative	Positive	Positive	Negative	
321		YES	YES					Negative	Negative	NT	Negative	NT	NT	NT	NT	Insufficient number of B cells, technical failure with T cells
351		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Cell viability too low to perform tests (60%)

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A06/2017 OS

DESPATCHED ON 23 MAY 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101															
112	1	1	8	1	1	1	2	1	1	8	2	1	90		
114					1	1	2	1	2	8	2	1			
116															
119	1	1	1	1									95		
120					1	1	8	1	1	8	8	1		100	100
128													98		
133					2	2	8	2	2	8	8	2	95	95	80
139	1	1	8	1	1	1	8	1	1	8	8	1	85	85	85
143					1	1	8	1						98.2	
145															
147	1	4	8	4	1	1	8	1	NT	NT	NT	NT	100	100	100
154															
157															
159					1	1	8	1	0.01	0.08	6	1		99	99
162							8			8	8			100	100
163					1	1	8	1	1	8	8	1		90	90
169					1	1	8	1		8	8			97	97
181					1	1	8	1	1	8	8	1	100	100	100
186					0	0	6	0	0	8	6	0		99	99
189	4	6	1	4									95		
190					1%	1%	1%	1%						99	60
193	1	2	8	1	1	1	8	1	1	8	8	1	97	98	95
194															
195					1	1	8	1						>95	
197															
204					1	1	8	1	2	8	8	1		100	95
206					0	0	6	0	0	8	8	0		95	80
209	1	4	4	1									90		
216	1	1	4	1									85		
223															
227							8				8			98	98
229															
232													80		
235	1	1	8	1									85		
238	1	4	8	1	1	1	8	1	1	8	4	1	95	95	80
239													90	90	90
245	1	2	6	1	1	1	6	1	1	8	6	1	100	100	100
252	2	2	6	2					2	6	6	2	85		70
259															
260	NT	NT	NT	NT	-	-	-	-	-	++++	-	-		90	80
262	1	1	4	1	1	1	1	1	4	8		6	100	100	100
268					1	1	8	1	1	4	2	1		98	80
284					1	1	8	1	1	8	8	1		97	30
292					1	1	6	1	4	8	6	1		85	60
293													12	10	5
294					2	0	8	0	0	8	8	0		95	90
297					1	1	8	1	1	6	8	1	80	80	80
321					1	1		1	NT	NT	NT	NT		95	20
351															